CN1087642A - 用于释放胞毒剂和其组分的方法 - Google Patents

用于释放胞毒剂和其组分的方法 Download PDF

Info

Publication number
CN1087642A
CN1087642A CN93109871A CN93109871A CN1087642A CN 1087642 A CN1087642 A CN 1087642A CN 93109871 A CN93109871 A CN 93109871A CN 93109871 A CN93109871 A CN 93109871A CN 1087642 A CN1087642 A CN 1087642A
Authority
CN
China
Prior art keywords
ethanoyl
phenyl
group
amino
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN93109871A
Other languages
English (en)
Chinese (zh)
Inventor
V·J·陈
L·N·容海姆
D·L·迈耶
T·A·谢泼德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybritech Inc
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of CN1087642A publication Critical patent/CN1087642A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being an antibiotic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN93109871A 1992-07-06 1993-07-06 用于释放胞毒剂和其组分的方法 Pending CN1087642A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90992492A 1992-07-06 1992-07-06
US909,924 1992-07-06

Publications (1)

Publication Number Publication Date
CN1087642A true CN1087642A (zh) 1994-06-08

Family

ID=25428053

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93109871A Pending CN1087642A (zh) 1992-07-06 1993-07-06 用于释放胞毒剂和其组分的方法

Country Status (6)

Country Link
CN (1) CN1087642A (es)
AU (1) AU4663493A (es)
IL (1) IL106228A0 (es)
MX (1) MX9304056A (es)
WO (1) WO1994001137A1 (es)
ZA (1) ZA934825B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025061A1 (en) * 1993-04-23 1994-11-10 Glyko, Inc. Methods and compositions for treating diseases with carbohydrate modifying enzymes
US5928888A (en) * 1996-09-26 1999-07-27 Aurora Biosciences Corporation Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and secondary screening capabilities
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
EP0454783B1 (en) * 1989-01-23 1995-06-07 Akzo Nobel N.V. Site specific in-vivo activation of therapeutic drugs
AU633867B2 (en) * 1989-02-02 1993-02-11 Eli Lilly And Company Delivery of cytotoxic agents
AU649275B2 (en) * 1990-11-06 1994-05-19 Bristol-Myers Squibb Company Prodrugs for beta-lactamase and uses thereof

Also Published As

Publication number Publication date
IL106228A0 (en) 1993-11-15
MX9304056A (es) 1994-05-31
WO1994001137A1 (en) 1994-01-20
AU4663493A (en) 1994-01-31
ZA934825B (en) 1995-01-05

Similar Documents

Publication Publication Date Title
JP6955042B2 (ja) 酵素的方法による均一抗体薬物コンジュゲート
WO2020090979A1 (ja) 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
CN105636612B (zh) 抗体-药物缀合物及使用和治疗方法
CN110526933B (zh) 生物素变体、链霉亲和素突变体以及它们的应用
US8664407B2 (en) Chemical linkers with single amino acids and conjugates thereof
EP0392745B1 (en) Immunoconjugates and prodrugs and their use in association for drug delivery
Schneider et al. Recent progress in transglutaminase-mediated assembly of antibody-drug conjugates
KR102076348B1 (ko) 사람 아르기나제 및 부위-지향성 페길화된 사람 아르기나제 및 그의 용도
RU2747581C2 (ru) Конъюгированные иммуноглобулины с c-концевым лизином
CN114395050A (zh) 鹅膏毒素-抗体轭合物
CN1044095A (zh) 大环双官能螯合剂、其配合物和它们的抗体共轭物
CN1826331A (zh) Pi－3激酶抑制剂前药
CN1511044A (zh) 可活化的药物前体中的加长的多间隔基
CN1956722A (zh) 含有新的美登素类的改进的细胞毒剂
CN101312748A (zh) 抗体-药物轭合物和使用方法
CN1074911A (zh) 将生物作用的物质结合至生物粒子面膜上的化合物，组合物和方法
CN1272841A (zh) 新的内酰胺金属蛋白酶抑制剂
CN1095677C (zh) 化合物
CN115551552A (zh) 喜树碱衍生物及其缀合物
CN1058595A (zh) 硫代烷硫基头孢菌素衍生物
JPH02247164A (ja) 細胞毒性剤の導入方法
CN1087642A (zh) 用于释放胞毒剂和其组分的方法
US20240123079A1 (en) Immunomodulatory antibody-drug conjugates
CN1668759A (zh) 具有抗糖尿病作用的物质的探索方法
US20230149558A1 (en) Duocarmycin derivative and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication